WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 6097

Legislative bill overview

HB 6097 requires prescription drug discount programs and pharmacy benefit managers to provide transparent disclosure of pricing, discounts, and negotiated rates to consumers and healthcare providers. The bill aims to increase visibility into drug pricing mechanisms that currently operate with limited public understanding of how final prices are determined.

Why is this important

Americans pay significantly more for prescription drugs than patients in other developed nations, yet the pricing mechanisms remain opaque to consumers and even providers. Greater transparency could empower patients to make informed choices, enable providers to guide patients toward more affordable options, and potentially reduce unnecessary costs by exposing inflated markups throughout the supply chain.

Potential points of contention

  • Industry opposition: Pharmacy benefit managers and discount program operators may argue that disclosing negotiated rates undermines their competitive position and could increase administrative costs that get passed to consumers
  • Implementation complexity: Requiring real-time or frequent disclosure of dynamic pricing across thousands of drugs and programs could impose substantial compliance burdens on already-complex systems
  • Proprietary information concerns: Drug manufacturers and PBMs may resist revealing negotiated discounts as trade secrets, claiming competitive harm and arguing that transparency could reduce their incentive to negotiate lower prices

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.